Cytek Biosciences, Inc. CTKB
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 207.65M | 206.71M | 204.17M | 201.49M | 196.83M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 207.65M | 206.71M | 204.17M | 201.49M | 196.83M |
| Cost of Revenue | 96.76M | 99.48M | 98.61M | 97.03M | 91.60M |
| Gross Profit | 110.89M | 107.23M | 105.56M | 104.46M | 105.23M |
| SG&A Expenses | 119.90M | 117.42M | 113.08M | 108.38M | 99.80M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 254.33M | 254.16M | 248.04M | 241.88M | 228.63M |
| Operating Income | -46.68M | -47.45M | -43.87M | -40.39M | -31.81M |
| Income Before Tax | -39.96M | -40.82M | -35.95M | -29.84M | -15.49M |
| Income Tax Expenses | 41.24M | 39.76M | 38.06M | 36.70M | -2.67M |
| Earnings from Continuing Operations | -81.20 | -80.58 | -74.00 | -66.54 | -12.82 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -81.20M | -80.58M | -74.00M | -66.54M | -12.82M |
| EBIT | -46.68M | -47.45M | -43.87M | -40.39M | -31.81M |
| EBITDA | -38.80M | -39.76M | -36.30M | -32.81M | -24.27M |
| EPS Basic | -0.63 | -0.63 | -0.58 | -0.52 | -0.10 |
| Normalized Basic EPS | -0.20 | -0.20 | -0.18 | -0.15 | -0.08 |
| EPS Diluted | -0.63 | -0.63 | -0.58 | -0.52 | -0.11 |
| Normalized Diluted EPS | -0.20 | -0.20 | -0.18 | -0.15 | -0.08 |
| Average Basic Shares Outstanding | 516.69M | 513.88M | 511.35M | 510.99M | 511.90M |
| Average Diluted Shares Outstanding | 516.69M | 513.88M | 511.35M | 510.99M | 511.90M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |